Ask about this productRelated genes to: HSD17B11 antibody
- Gene:
- HSD17B11 NIH gene
- Name:
- hydroxysteroid 17-beta dehydrogenase 11
- Previous symbol:
- DHRS8
- Synonyms:
- RetSDR2, 17-BETA-HSD11, 17-BETA-HSDXI, PAN1B, SDR16C2
- Chromosome:
- 4q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-12-02
- Date modifiied:
- 2016-06-03
Related products to: HSD17B11 antibody
Related articles to: HSD17B11 antibody
- Circulating cytokines/chemokines are linked to checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). The tumor-immune microenvironment (TIME) plays a significant role in modulating a broad range of cytokines and chemokines. This study aimed to explore the crosstalk between circulating cytokines/chemokines and TIME, related to ICIs outcomes. - Source: PubMed
Publication date: 2026/01/14
Mai Van HieuPrasanpanich MarisaZungsontiporn NichaKorphaisarn KrittiyaSitthideatphaiboon PiyadaAporntewan ChatchawitChantranuwat PoonchavistHirankarn NattiyaVinayanuwattikun Chanida - Perfluorooctanoic Acid (PFOA), widely recognized as an enduring environmental pollutant, is associated with immune system disruption and potential cancer-causing effects. Epidemiological findings show that serum power is significantly associated with inflammatory bowel disease (IBD). However, the specific mechanisms driving these effects remain poorly understood. - Source: PubMed
Publication date: 2025/12/15
Chen GangYuan HangLi XiaoPengChen ShihuiSun XuejunYu Junhui - Phenyl dialkynylcarbinols (PACs) are analogues of natural acetylenic lipids acting on human cells as cytotoxic prodrugs enantiospecifically bioactivated by HSD17B11. Here, we report a highly convergent and modular synthetic strategy to accelerate the exploration of their anticancer structure-activity relationships. Late-stage PAC assembly was achieved by Pd/Cu-catalysed coupling of three chiral alkynylcarbinol warheads, racemic or enantioenriched, with various functionalised lipidic aryl iodides. The added value of this methodology to directly access enantioenriched PAC analogues from an enzymatically resolved alkynylcarbinol precursor was also demonstrated. A total of 22 new compounds were prepared, including two butadiynylcarbinol congeners, with IC values as low as 0.13 μM in HCT116 cancer cells. Enantiomeric comparisons confirmed strong eudismic ratios in this series. Genetic inactivation of HSD17B11 in U2OS cells demonstrated its key role in the cytotoxicity of most compounds, while 1,2,3-triazolyl allenyl alkynylcarbinols emerged as particularly promising, combining a novel chemotype, a potent activity, and an alternative mechanism of action. - Source: PubMed
Publication date: 2025/10/14
Bossuat MargauxPreuilh NadègeSeigneur PatrickFabing IsabellePradel ChristianPeixoto AntonioMaraval ValérieBernardes-Génisson VaniaBallereau StéphanieBritton SébastienGénisson Yves - Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related mortality worldwide. Mendelian randomization (MR) has emerged as a powerful approach for therapeutic target identification in HCC. In this study, we applied two-sample MR to assess the causal effects of multiple genes on HCC risk. Replication analyses integrated summary-data-based MR, Bayesian co-localization, and protein-protein interaction networks with druggability assessment to prioritize targets. Single-cell RNA sequencing validated cell-type-specific expression patterns in T cells, endothelial cells, and hepatocytes. MR-, summary-data-based MR-, and co-localization-based approaches identified target genes associated with HCC risk, comprising 3 first-level targets (HLA-DPA1, MBTPS1, and TIMP3), 2 second-level targets (TNXB and HSD17B11), and also 4 tertiary targets (HLA-DPB1, PLD2, KLHL8, and TGFBR1). All in all, this research identifies several potential therapeutic targets relevant to the risk of HCC and provides new insights into the identification of therapeutic agents for the treatment of HCC. - Source: PubMed
Tang ChaoZhu ShuangjingDing Zhen - Fatigue is a prevalent and debilitating symptom of non-communicable diseases (NCDs); however, its biological basis are not well-defined. This exploratory study aimed to identify key biological drivers of fatigue by integrating metabolomic, microbiome, and genetic data from blood and saliva samples using a multi-omics approach. - Source: PubMed
Publication date: 2025/06/03
Kobayashi YusukeFujiwara NaokiMurakami YukiIshida ShoichiKinguchi ShoHaze TatsuyaAzushima KengoFujiwara AkiraWakui HiromichiSakakura MasayoshiTerayama KeiHirawa NobuhitoIsozaki TetsuoYasuzaki HiroakiTakase HajimeYano YuichiroTamura Kouichi